Penn Neuroradiology 'Brain Tumor Retreat'
Emerging Concepts in the Management of Glioblastoma
'From Temozolomide to Tumor Treating Fields'
Wednesday, October 4, 2017 from 5 PM to 9 PM
Location: Rubenstein Auditorium, 1st Floor, Smilow Center for Translational Research
Glioblastoma (GBM) is the most common malignant brain tumor and accounts for 70% of all primary brain tumors in adults. Despite aggressive multi-modal therapy including surgery, radiation, and chemotherapy, the prognosis remains poor with a median survival of around 2 years. Although these statistics are daunting, recent advances in the understanding of brain tumor biology have fueled a new sense of optimism with development of more effective and less toxic therapies.
This “Brain Tumor Retreat” will discuss current concepts of brain tumor management with special emphasis toward novel therapeutic approaches. We will discuss current standard-of-care and practice-changing landmark clinical trials in the management of GBM. Novel physiologic and metabolic neuroimaging techniques will be discussed including their role in treatment planning and in assessing response.
- Review the current treatment of GBM and highlight novel directions and opportunities for innovative therapies.
- Understand the intimate relationship of brain tumors to critical structures and role of upcoming neuroimaging techniques that can aid to provide real-time evaluation of the tumor metabolism, and assess for treatment response.
- Highlight areas of substantial progress and extraordinary opportunity in the field of neuro-oncology.
Register by Monday, September 25, 2017.
Dinner, cocktails and dessert will be served.
Space is limited.